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The development of ophthalmic formulations is a major challenge. The most commonly used 
ophthalmic formulations are eye drops which have low bioavailability due to the complex 
structure and the elimination mechanisms of the eye [1].  
Nanostructured lipid carrier (NLC) is the term used for the second-generation solid lipid 
nanoparticles that contain a lipid matrix of mixed solid and liquid lipids. These systems are 
ideal to incorporate low water-soluble active substances such as corticosteroids [2]. 
The aim of this work was to create a dexamethasone (DXM) loaded NLC formulation to 
increase the bioavailability of DXM, which is a lipophilic drug with poor solubility in water. As 
a preformulation study, lipid screening (visual observation, XRD, DSC measurements and 
investigation of blank NLCs) were applied to choose the most suitable excipients for the 
formulation of the system. A 23 factorial design was used to investigate the effects of the 
excipients on zeta potential, mean particle size, PDI and entrapment efficacy. The 
independent factors were lipid, DXM and surfactant concentration. Based on the one-month 
stability test, a lower surfactant and lipid concentration could be beneficial. The ophthalmic 
toxicity was investigated on human cornea cells and the results show that the measured NLC 
formulations have good ophthalmic tolerability. The in vitro drug release study suggests that 
the NLC formulations increase the diffused amount of DXM in the acceptor phase, while the 
penetration study on porcine cornea with Raman mapping predicted a higher amount of 
nanocarriers in the stroma layer.  
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